cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Veracyte Inc
2 own
5 watching
Current Price
$26.67
$-1.22
(-4.37%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,913.35M
52-Week High
52-Week High
33.23
52-Week Low
52-Week Low
14.85
Average Volume
Average Volume
0.55M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,913.35M
icon52-Week High33.23
icon52-Week Low14.85
iconAverage Volume0.55M
iconDividend Yield--
iconP/E Ratio--
What does the Veracyte Inc do?
Veracyte, Inc. operates as a molecular diagnostics company in the United States. The company uses genomic technology to resolve diagnostic ambiguity. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The company's products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. It sells its products through its product specialists, institutional channel managers, account managers, and clinical science specialists. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Read More
How much money does Veracyte Inc make?
News & Events about Veracyte Inc.
Business Wire
3days ago
Veracyte, Inc. (Nasdaq: VCYT) today announced that data published in Frontiers in Endocrinology provide new insights into the frequency and risk of malignancy (ROM) associated with thyroid stimulating hormone receptor (TSHR) mutations in indeterminate thyroid nodules. The findings, which were...
Globe Newswire
12days ago
SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN),a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023. Dr. Nova succeeds Brian Birk, who has ...
Ticker Report
2 months ago
Veracyte (NASDAQ:VCYT Get Rating) had its target price raised by SVB Leerink from $30.00 to $35.00 in a research report released on Thursday morning, MarketBeat Ratings reports. The firm currently has an outperform rating on the biotechnology companys stock. Other equities research ...
Business Wire
3 months ago
Veracyte, Inc. (Nasdaq: VCYT) announced new data demonstrating that a genomic signature derived from the companys Decipher GRID database could help determine which men experiencing prostate cancer progression following radical prostatectomy (RP) would benefit from dose-intensified salvage...
Business Wire
3 months ago
Veracyte, Inc. (Nasdaq: VCYT) today announced data that provide new insights into thyroid tumor behavior. The findings were derived from whole-transcriptome analyses of Veracytes extensive thyroid nodule database and were presented at the American Thyroid Association Annual Meeting, held October...
Frequently Asked Questions
Frequently Asked Questions
What is Veracyte Inc share price today?
plus_minus_icon
Can Indians buy Veracyte Inc shares?
plus_minus_icon
How can I buy Veracyte Inc shares from India?
plus_minus_icon
Can Fractional shares of Veracyte Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Veracyte Inc stocks?
plus_minus_icon
What is today’s traded volume of Veracyte Inc?
plus_minus_icon
What is today’s market capitalisation of Veracyte Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Veracyte Inc?
plus_minus_icon
What percentage is Veracyte Inc down from its 52-Week High?
plus_minus_icon
What percentage is Veracyte Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$26.67
$-1.22
(-4.37%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
BeiGene Ltd
BeiGene Ltd
$256.90
$1.85 (0.73 %)
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$68.70
$-5.59 (-7.52 %)
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
$30.20
$0.02 (0.07 %)
MacroGenics, Inc.
MacroGenics, Inc.
$5.59
$-0.33 (-5.57 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
BeiGene Ltd
BeiGene Ltd
$256.90
$1.85 (0.73 %)
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$68.70
$-5.59 (-7.52 %)
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
$30.20
$0.02 (0.07 %)
MacroGenics, Inc.
MacroGenics, Inc.
$5.59
$-0.33 (-5.57 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00